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Purpose: To determine the sensitivity of spectral domain ocular coherence tomography 
(SD-OCT) and fundus auto fluorescence (FAF) images as a screening test to detect early 
changes in the retina prior to the onset of chloroquine retinopathy.
Method: The study was conducted using patients taking chloroquine (CQ), referred by 
the Rheumatology Department to the Ophthalmology Department at Tygerberg Academic 
Hospital. Group A consisted of 59 patients on CQ for less than 5 years, and Group B consisted 
of 53 patients on CQ for more than 5 years. A 200 × 200 macula thickness map, 5-line raster 
SD-OCT on a Carl Zeiss Meditec Cirrus HD-OCT and FAF images on a Carl Zeiss Meditec 
Visucam 500 were recorded for 223 eyes. Images were reviewed independently, and then 
those of Groups A and B compared.
Results: There were no statistically significant differences between Groups A and B. The 
criteria included the internal limiting membrane and the retinal pigment epithelium (ILM-RPE) 
thickness, interdigitation zone integrity (p = 0.891, df = 1, χ² = 0.1876), ellipsoid zone integrity 
(p = 0.095, df = 2, χ² = 4.699) and FAF image irregularities (p = 0.479, df = 1, χ² = 4995978).
Conclusion: The inclusion of SD-OCT and FAF as objective tests into the prescribed screening 
guidelines does not appear to simplify the detection of subclinical injury in patients on 
chloroquine treatment.
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Introduction
Antimalarials such as chloroquine (CQ) and hydroxychloroquine (HCQ) have been used to treat 
rheumatoid illnesses since the 1950s. Both these agents are thought to cause ocular toxicity.1,2,3 
It has been shown that HCQ has a lower incidence of toxic retinopathy than CQ.4 However, a 
retrospective case control study using 2361 patients showed a prevalence of toxicity in 7.5% of 
patients taking HCQ for ≥ 5 years.5
The safe daily dose and cumulative dose of CQ use is unclear6,7 as there is a high variability 
regarding which cumulative dosage leads to retinopathy.8 Information published by the 
American Academy of Ophthalmology (AAO) in February 2011 stated that (1) a daily dose 
> 400 mg of HCQ (> 6.5 mg/kg ideal body weight for short individuals) and > 250 mg daily of 
CQ (> 3.0 mg/kg ideal body weight for short individuals), (2) a cumulative dose > 1000 g of 
HCQ and 460 g of CQ, (3) therapy duration > 5 years, (4) patient age, (5) other retinal and macula 
diseases, (6) renal and kidney disease and (7) genetic factors are known to modify patient risk.9
There has been a decrease in retinopathy in Western countries where HCQ has been used as a 
replacement for CQ. However, in South Africa, HCQ is not available to patients attending public 
clinics and hospitals.
Literature review
Antimalarials are excreted from the body very slowly and are melanotropic drugs. These drugs 
accumulate in structures such as the retinal pigment epithelium (RPE) and choroid. Photoreceptor 
degeneration is seen owing to increased deposits in the RPE, which in turn leads to increased 
phagocytic activity and lipofuscin accumulation.10
Five stages of chloroquine retinopathy have been described by Kanski.11 Pre-maculopathy is the 
first stage where there is a normal visual acuity but also a paracentral scotoma to a red target 
between 4 and 9 degrees. This stage is then followed by a slight reduction in visual acuity and 
a subtle ‘bull’s eye’ lesion; these changes may be reversed if the drug is discontinued. Screening 
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techniques have been implemented to detect early changes 
so as to prevent progression of the disease.
Fundus auto fluorescence (FAF) records RPE lipofuscin 
deposition, which is a mixture of fluorophores.12 Lipofuscin 
has the characteristic of autofluorescence when exposed 
to UV or blue light.10 The retina exhibits visible changes in 
patients taking CQ or HCQ, such as a pericentral ring of 
increased intensity as seen in patients with mild retinopathy, 
whilst patients with more advanced retinopathy have a 
more mottled appearance with variations in intensity in the 
pericentral macula. The image of a healthy macula on FAF 
has low autofluorescence at the fovea owing to low lipofuscin 
concentration. Autofluorescence increases minimally to 
about 7 degrees – 13 degrees from the fovea.13,14 Generally, 
FAF is not symmetrically distributed around the fovea.
Changes in the RPE visible on FAF are also associated with 
alterations of the photoreceptor inner and outer segment 
boundary (IS/OS), and thinning of the outer nuclear layer of 
the retina is seen on SD-OCT.15
In 2002, the AAO published preferred practice patterns 
(PPP) for CQ and HCQ retinopathy. The suggested screening 
examinations included a dilated fundus examination, visual 
field assessment with either an Amsler grid or Humphrey 
Visual Field Analyser, measuring the central 10 degrees of 
vision, colour vision testing and fundus photography. Both 
fluorescein angiography and multifocal electroretinography 
(mfERG) are considered optional.16 Revisions as published 
(AAO, February 2011) recommended that the Amsler grid 
be removed from the list of tests and that a 10–2 Humphrey 
visual field be supplemented with sensitive objective tests 
such as the mfERG, FAF and SD-OCT.9
Importance of the study
At present, there is no gold standard for CQ retinopathy 
diagnosis; however, as per the revised recommendations, 
a dilated fundus examination and visual field testing are 
considered compulsory examination procedures for a patient 
taking CQ. Whilst clinical examination is vitally important, 
small changes are difficult to record and recall. Visual field 
testing is subjective, leaving room for error, as the patient’s 
cooperation and understanding are vitally important for a 
reliable result. FAF and SD-OCT are relatively new imaging 
devices for the ophthalmologist. The tests are objective and 
serial images can be taken and recorded over time.
The AAO guideline9 recommends that a baseline examination 
and record keeping of fundus images should take place 
within the first year of starting CQ treatment, and follow-up 
should be annually after 5 years of treatment. Despite this 
recommendation, follow-up currently in South Africa takes 
place either bi-annually or annually throughout the course 
of treatment, without a five-year delay as suggested. For 
this reason, we compared retinal changes in patients taking 
CQ for more than 5 years with those using CQ for less than 
5 years.
Objectives of the study
The study evaluated FAF and SD-OCT as screening tests to 
prophylactically detect early changes in the retina leading 
to CQ retinopathy. The primary aim was to determine 
whether there were any differences in the number of visible 
retinal changes suggestive of CQ retinopathy between 
patients on CQ treatment for more than 5 years compared 
with those on less than 5 years, using FAF images and 
SD-OCT.
Methods
The study was conducted using patients taking CQ 
chronically for various diseases, referred by the Rheumatology 
Department at Tygerberg Hospital to the Ophthalmology 
Department at the same hospital. The process included a 
current review of FAF images and SD-OCT images of these 
patients. FAF imaging was performed on the Carl Zeiss 
Meditec Visucam 500, and SD-OCT imaging on the Carl Zeiss 
Meditec Cirrus HD-OCT. Tygerberg Academic Hospital is a 
tertiary hospital, the second biggest of its kind in South 
Africa. Currently, screening includes a 10–2 Humphrey 
visual field examination, a dilated fundus examination, and 
FAF and SD-OCT imaging. All patients were referred as 
standard practice, and not solely on complaint or deterioration 
of visual acuity, on request of the rheumatologist.
Information regarding dosage, cumulative dosage, weight 
and years on treatment was obtained from both the patient 
and the patient’s hospital file.
Consent was obtained from 112 patients (223 eyes [111 right 
eyes {one patient was monocular owing to a previous 
evisceration from trauma} and 112 left eyes]); 101 (90.2%) 
female participants and 11 (9.8%) male participants. The age 
range was 5.6–87.8 years.
Results
Group A consisted of 59 patients on CQ for less than 5 years, 
and Group B consisted of 53 patients on CQ for more than 
5 years.
Table 1 shows various participant characteristics as well as 
primary diagnosis and cumulative dosage of CQ.
For the macular map, the four quadrants of the outer, 6 mm 
diameter ring around the fovea were labelled S6, T6, I6, and 
N6 to represent the superior, temporal, inferior and nasal 
regions, respectively. The inner, 3 mm diameter ring was 
labelled analogously. C1 represents the innermost 1 mm 
diameter ring around the fovea17 (Figure 1).
Figure 2 shows a box and whisker plot of the C1 ring in 
Groups A and B measured with SD-OCT, and Figure 3 shows 
the correlation between C1 and cumulative dosage.
Tables 2 and 3 compare macula thickness between Groups 
A and B.
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Spectral domain ocular coherence tomography 
Ellipsoid zone
Analysis of the ellipsoid zone revealed 186 normal 
ellipsoid zones (98 in Group A; 88 in Group B). Three were 
classified as questionably abnormal (3 in Group A; 0 in 
Group B) and 26 were classified as abnormal (10 in Group 
A; 16 in Group B) (Table 4).
Of the abnormal and questionable images seen in Group A, 
7 had focal abnormalities (viz. confined to one specific area), 
4 had diffuse abnormalities and 1 had both focal and diffuse 
TABLE 1: Patient characteristics in Groups A and B using chloroquine for less 
than or more than 5 years.
Patient characteristics Duration on chloroquine
< 5 years > 5 years
Age
Mean age and standard deviation (years) 50.04 ± 15.67 54.59 ± 9.8
Gender
Male 6 (10.17) 5 (9.44)
Female 53 (89.83) 48 (90.56)
Race
Mixed race 44 (74.58) 41 (77.36)
Somalian 1 (1.69) 0
White 4 (6.78) 4 (7.56)
Black 8 (13.56) 6 (11.32)
Unknown 2 (3.39) 2 (3.76)
Primary diagnosis
Rheumatoid arthritis 32 (54.24) 32 (60.39)
Systemic lupus erythematosis (SLE) 15 (25.43) 15 (28.30)
Discoid lupus erythematosis (DLE) 5 (8.47) 2 (3.77)
Osteoarthritis 1 (1.69) 2 (3.77)
Mixed connective tissue disease 1 (1.69) 2 (3.77)
Systemic sclerosis 3 (5.09) 0 (0.00)
Sarcoidosis 2 (3.39) 0
Cumulative dosage
2 days 1 (1.69) 0
4 days 14 (23.74) 16 (30.18)
5 days 42 (71.19) 34 (64.16)
6 days 1 (1.69) 2 (3.77)
7 days 1 (1.69) 1 (1.89)
S6
S3
C1 T3 T6N3N6
I3
I6
Note: The inner, 3 mm diameter ring is labelled analogously. C1 represents the innermost 
1 mm diameter ring around the fovea.17
FIGURE 1: Macular map: the four quadrants of the outer, 6 mm diameter ring 
around the fovea are labelled S6, T6, I6 and N6 to represent the superior, 
temporal, inferior and nasal regions, respectively.17
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FIGURE 2: Box and whisker plot of central 1 mm thickness of the ILM and RPE (C1) 
in Group A and Group B measured with SD-OCT.
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Note: There was no correlation between central subfield thicknesses (C1) and cumulative 
dosage of chloroquine (r = 0.05, p = 0.49).
FIGURE 3: Correlation between central subfield thickness (C1) (µm) on SD-OCT 
and cumulative dosage (g).
TABLE 2: Comparisons of all retinal thickness layers as per the macula map with 
the chi-square statistic between Group A (< 5 years on chloroquine) and Group 
B (> 5 years on chloroquine) (df = 4).
Layer Pearson chi-square statistic p value
S6 5.863 0.209
T6 3.776 0.437
I6 4.096 0.393
N6 4.724 0.317
S3 3.024 0.554
T3 3.97 0.41
I3 3.542 0.472
N3 8.577 0.073
C1 1.413 0.842
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abnormalities. Those with focal abnormalities had a distinct 
blurring below the foveal dip. This blurring was the most 
common abnormality detected in the study.
Of the abnormal images seen in Group B, 8 had focal 
abnormalities and 6 had diffuse abnormalities. Two were not 
classified.
Interdigitation zone
Analysis of the interdigitation zone revealed 203 normal-
looking interdigitation zones (106 in Group A; 97 in Group B), 
and 10 abnormal (5 in Group A; 5 in Group B). Of the 
abnormal images seen in Group A, 2 had focal abnormalities 
and 3 had diffuse abnormalities (Table 5).
In Group B, 2 eyes had focal abnormalities and 2 had diffuse 
abnormalities. The 5th eye was classified as abnormal in this 
area owing to CHRPE (congenital hypertrophy of the retinal 
pigment epithelium).
Retinal pigment epithelium
Analysis of the RPE revealed the lowest number of visible 
changes, with 1 abnormal image and 1 questionable image.
Other abnormalities
In Group A, 3 images with unusually shaped macula dips 
were seen and 1 epi-retinal membrane was found. In Group B, 
1 image with an unusually shaped macula dip was seen, 1 
intra-retinal cyst, 1 epi-retinal membrane, 1 with oedema, 
and 2 with high myopia.
When comparing the occurrence of other abnormalities on 
SD-OCT between Group A and Group B with a paired t-test, 
a non-statistically significant result was produced (p = 309, 
df = 4, χ² = 4.79).
Macula cube
Two hundred and fourteen 200 × 200 macula thickness cube 
images were assessed. Group A consisted of 111 images, and 
Group B of 103. However, only 107 in Group A had assigned 
distributions (4 images were of 2 patients under 18 years 
of age and no normative values were available). The value 
of the distribution was thought to be most relevant, as the 
distribution was compared with normative data in relation 
to age. For each area of the macula cube, both in Group A 
and B, the mean distribution was ’green’, indicating that 90% 
of the measurements fell within those values. As seen in the 
analysis, when comparing the distribution profile between 
Groups A and B individually for all 9 areas (S6, T6, I6, and 
N6, S3, T3, I3, and N3 and C1), the p values showed no 
statistical significance, which indicates that the distribution 
profile does not differ between those on CQ for more or less 
than 5 years. This finding is therefore not a clear indicator of 
subclinical macula pathology.
Fundus auto fluorescence
Images of 213 (109 in Group A and 104 in Group B) FAF 
images were assessed for any visible changes (Table 6). 
At present, there is no standardised or known grading 
system for interpretation or zoning of FAF irregularities or 
abnormalities. For this reason, we stated that any changes 
occurring within the arcades would be regarded as ‘central’ 
and those outside the arcades as ’peripheral’. Our impression 
is that the appearance of an FAF image differs depending 
on the race, and therefore the pigmentation, of the patient. 
Those with more pigmentation had an overall darker-looking 
image, in comparison with those with less pigmentation.
The proportion of normal images in Group A (85.3%) is slightly 
greater than that in Group B (81.7%) but, when compared by 
a paired t-test, the difference was not statistically significant 
(p = 0.477). Most abnormalities were found centrally (Group 
A 81.2%; Group B 55.5%), some were found both centrally 
and peripherally (Group A 6.3%; Group B 22.2%) and only in 
Group B were abnormalities found at the fovea (Group A 0%; 
Group B 16.7%) (Table 7).
Most of the abnormalities seen were small localised areas of 
hypo auto fluorescence (Group A 37.5%; Group B 17.7%).
TABLE 3: Macula map thickness distributions compared with a t-test for independent samples between Groups A (107 values) and B (103 values).
Variable Mean < 5 years (Group A) Mean ≥ 5 years (Group B) t-value df p
S6 (distribution) 2.96 3.11 1.609 208 0.109
T6 (distribution) 3.02 3.12 1.253 208 0.212
I6 (distribution) 3.07 3.16 0.903 208 0.368
N6 (distribution) 2.99 3.08 1.04 208 0.299
S3 (distribution) 3.18 3.13 -0.582 208 0.561
T3 (distribution) 3.21 3.19 -0.239 208 0.815
I3 (distribution) 3.18 3.2 0.296 208 0.768
N3 (distribution) 3.16 3.15 -0.156 208 0.876
C1 (distribution) 3.18 3.17 -0.148 208 0.882
TABLE 4: Ellipsoid zone integrity analysis.
Integrity Group A % Group B % Total
Normal 98 84.62 88 88.29 186
Questionable 3 2.7 0 0 3
Abnormal 10 9.01 16 15.38 26
Total 111 - 104 - 215
TABLE 5: Interdigitation zone integrity analysis.
Integrity Group A % Group B % Total
Normal 106 95.50 97 95.10 203
Abnormal 5 4.50 5 4.90 10
Total 111 - 102 - 213
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Discussion
The 2011 revised AAO screening guidelines for CQ and HCQ 
retinopathy suggest a Humphrey 10–2 visual field, dilated 
fundus examination and the use of an objective test such 
as SD-OCT and FAF.9 In our study using these tests on 223 
eyes, we found a low incidence of CQ retinopathy, probably 
indicating a fairly low degree of ocular toxicity.
After extensive review of all images, there were no signs 
from SD-OCT or FAF that required a decision to be made 
regarding cessation of CQ treatment in any of the patients. 
The changes seen in those on CQ treatment for less than 
5 years did not differ significantly from those on CQ for more 
than 5 years, which may suggest that the 5-year cut-off for 
more intensive screening is premature. These investigations 
may assist us at baseline prior to initiating CQ therapy to 
investigate underlying retinal disease.
The use of a 5-line raster with SD-OCT as an assessment for 
early CQ retinopathy detection did not prove to provide us 
with additional insight. It is interesting to note that the most 
common change seen was a ‘blurry’ central area under the 
macula dip.
At the present stage of retinal imaging, it may be more 
difficult to detect early abnormalities with FAF as it is less 
quantitative than other methods.
Recent publications have demonstrated that the cumulative 
dosage related to real body weight is a large factor in 
development of retinopathy, together with other factors such 
as kidney disease and additional medication use.5
Conclusion
Future studies comparing more disparate groups, such as 
those on treatment for only 1 year to those on treatment for 
10 years or more, may be useful to determine at which stage 
the occurrence of CQ retinopathy increases, and assist in 
determining an appropriate stage at which more intensive 
screening becomes valuable. Additional research is needed 
to determine whether our population group, which was 
mostly that of mixed-race ethnicity (see Table 1), has a lower 
incidence of CQ retinopathy, as well as studies with a larger 
sample size, to detect changes with greater power.
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